VQW-765

DRUG2 trials

Sponsors

Vanda Pharmaceuticals

Conditions

Performance AnxietySocial Anxiety Disorder (SAD)

Phase 2

Evaluating the Effects of VQW-765 vs. Placebo in Performance Anxiety

CompletedNCT04800237

Vanda PharmaceuticalsPerformance Anxiety

Start: 2021-02-23End: 2022-08-02Updated: 2024-03-20

Phase 3

Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder

Active, not recruitingNCT07221578

Vanda PharmaceuticalsSocial Anxiety Disorder (SAD)

Start: 2025-09-22End: 2027-04-01Target: 500Updated: 2026-08-17